Agomab Therapeutics NV ('Agomab') today announced the closing of a $100 million Series C round of financing to support the Phase 2a clinical trial evaluating Agomab's lead drug candidate, AGMB-129, a ...
Asabys has announced that the Institut Català de Finances (ICF) has joined its new venture capital fund, Sabadell Asabys Health Innovation Investments II (Sabadell Asabys II), with 10 million euros. ...
En los últimos dos años hemos vivido una transformación en la industria sanitaria, viendo como dos grandes industrias, independientes y en constante evolución, se acercaban hasta acabar convergien...
Asabys Partners, a venture capital firm and member of CataloniaBio & HealthTech, has participated in Medasense Biometrics Ltd’s €15.2-million Series C round of funding along with investors such as...
Asabys Partners (“Asabys”), a Pan-European Venture Capital firm specialized in investments in the life sciences and health sectors, and Alantra, an investment banking and asset management firm...
Desde sus respectivos ámbitos de actividad, IQS y Asabys Partners comparten el reto de impulsar soluciones de futuro en las áreas de la salud, la biomedicina y la industria biofarmaceútica.